Sparks commentary - Newron Pharmaceuticals

Healthcare

Sparks - Newron Pharmaceuticals

More on this equity
Newron Pharmaceuticals (SIX: NWRN) extends EIB loan
Published by Arron Aatkar, PhD

Newron Pharmaceuticals has announced an agreement with the European Investment Bank (EIB) to amend certain terms of the 2018 Finance Contract and Options Rights Agreement, as previously amended in 2024. Now, the parties have agreed to extend the maturity date of all outstanding tranches under the Finance Contract to 28 June 2028. Importantly, this is beyond the expected key readouts from the registrational ENIGMA-TRS Phase III programme.